Orlistat for drug resistance after targeted therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the weight-loss drug orlistat can help people whose lung cancer has stopped responding to third-generation targeted pills. It may help the targeted treatment work again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have taken a third-generation targeted therapy (like osimertinib or similar) and it stopped working.
- You are able to do everyday activities with minimal help (ECOG score 0-2).
- You are expected to live more than 3 months.
- Your blood counts, liver, kidney, and clotting function are within acceptable limits.
- You are willing and able to keep taking the oral targeted drug.
- You are not pregnant or breastfeeding, and you do not have serious uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
This study tests whether a targeted therapy pill called osimertinib can help people whose lung cancer has returned after they already received targeted therapy following surgery. The goal is to see if this treatment can control the cancer and improve outcomes.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.